{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=29",
    "query": {
      "condition": "Metastatic Solid Tumor Cancers",
      "page": 29
    },
    "page_size": 10
  },
  "pagination": {
    "page": 29,
    "page_size": 10,
    "total_count": 1752,
    "total_pages": 176,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=30&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Metastatic+Solid+Tumor+Cancers&page=28&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-15T20:56:03.532Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT00909831",
      "title": "Hydroxychloroquine and Temsirolimus in Treating Patients With Metastatic Solid Tumors That Have Not Responded to Treatment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "hydroxychloroquine",
          "type": "DRUG"
        },
        {
          "name": "temsirolimus",
          "type": "DRUG"
        },
        {
          "name": "electron microscopy",
          "type": "OTHER"
        },
        {
          "name": "high performance liquid chromatography",
          "type": "OTHER"
        },
        {
          "name": "immunologic technique",
          "type": "OTHER"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "mass spectrometry",
          "type": "OTHER"
        },
        {
          "name": "pharmacological study",
          "type": "OTHER"
        },
        {
          "name": "autophagy inhibition therapy",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "Abramson Cancer Center at Penn Medicine",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 40,
      "start_date": "2008-10",
      "completion_date": "2013-11",
      "has_results": false,
      "last_update_posted_date": "2019-04-16",
      "last_synced_at": "2026-10-15T20:56:03.532Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00909831"
    },
    {
      "nct_id": "NCT00547677",
      "title": "Stereotactic Radiosurgery for Patients With Hepatic Metastases.",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Metastatic Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "stereotactic radiosurgery",
          "type": "RADIATION"
        }
      ],
      "intervention_types": [
        "RADIATION"
      ],
      "sponsor": "University of Texas Southwestern Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "18 Years to 120 Years"
      },
      "enrollment_count": 27,
      "start_date": "2004-07",
      "completion_date": "2008-12",
      "has_results": false,
      "last_update_posted_date": "2019-02-15",
      "last_synced_at": "2026-10-15T20:56:03.532Z",
      "location_count": 2,
      "location_summary": "Minneapolis, Minnesota • Dallas, Texas",
      "locations": [
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Dallas",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00547677"
    },
    {
      "nct_id": "NCT00437437",
      "title": "A Phase I Study to Determine the Effect of Food on Brivanib (BMS-582664)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Tumors"
      ],
      "interventions": [
        {
          "name": "Brivanib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 29,
      "start_date": "2000-05",
      "completion_date": "2013-02",
      "has_results": false,
      "last_update_posted_date": "2013-06-21",
      "last_synced_at": "2026-10-15T20:56:03.532Z",
      "location_count": 3,
      "location_summary": "Boston, Massachusetts • Detroit, Michigan • Durham, North Carolina",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Detroit",
          "state": "Michigan"
        },
        {
          "city": "Durham",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00437437"
    },
    {
      "nct_id": "NCT04134312",
      "title": "A Phase 1 Open Label Trial of Intravenous Administration of MVA-BN-Brachyury Vaccine in Patients With Advanced Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Solid Metastatic Tumor"
      ],
      "interventions": [
        {
          "name": "MVA-BN-Brachyury",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Bavarian Nordic",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 13,
      "start_date": "2020-01-08",
      "completion_date": "2021-04-06",
      "has_results": false,
      "last_update_posted_date": "2021-07-14",
      "last_synced_at": "2026-10-15T20:56:03.532Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04134312"
    },
    {
      "nct_id": "NCT01327612",
      "title": "Open Label Extension Study of Conatumumab and Ganitumab (AMG 479)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Advanced Solid Tumors",
        "Carcinoid",
        "Colorectal Cancer",
        "Locally Advanced",
        "Lymphoma",
        "Metastatic Cancer",
        "Non-Small Cell Lung Cancer",
        "Sarcoma",
        "Solid Tumors"
      ],
      "interventions": [
        {
          "name": "Modified FOLFOX6",
          "type": "DRUG"
        },
        {
          "name": "Conatumumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Ganitumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Bevacizumab",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Amgen",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 12,
      "start_date": "2011-03-03",
      "completion_date": "2020-02-05",
      "has_results": true,
      "last_update_posted_date": "2021-02-21",
      "last_synced_at": "2026-10-15T20:56:03.532Z",
      "location_count": 10,
      "location_summary": "Duarte, California • La Jolla, California • Denver, Colorado + 7 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01327612"
    },
    {
      "nct_id": "NCT02014337",
      "title": "Mifepristone and Eribulin in Patients With Metastatic Triple Negative Breast Cancer or Other Specified Solid Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Breast Cancer",
        "Ovarian Epithelial Cancer Recurrent",
        "Sarcoma",
        "Non-small Cell Lung Cancer",
        "Carcinoma, Transitional Cell",
        "Prostate Cancer",
        "Prostatic Neoplasms"
      ],
      "interventions": [
        {
          "name": "Mifepristone and Eribulin in combination",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Corcept Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 37,
      "start_date": "2014-01",
      "completion_date": "2017-12",
      "has_results": false,
      "last_update_posted_date": "2018-01-17",
      "last_synced_at": "2026-10-15T20:56:03.532Z",
      "location_count": 11,
      "location_summary": "Tucson, Arizona • Tampa, Florida • Atlanta, Georgia + 8 more",
      "locations": [
        {
          "city": "Tucson",
          "state": "Arizona"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Royal Oaks",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02014337"
    },
    {
      "nct_id": "NCT03746431",
      "title": "A Phase 1 Study of [225Ac]-FPI-1434 Injection",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Solid Tumours",
        "Endometrial Cancer",
        "Cervical Cancer",
        "Ovarian Cancer",
        "Breast Cancer",
        "Triple Negative Breast Cancer (TNBC)",
        "HER2-negative Breast Cancer",
        "Head and Neck Squamous Cell Carcinoma (HNSCC)",
        "Adrenocortical Carcinoma",
        "Uveal Melanoma"
      ],
      "interventions": [
        {
          "name": "[111In]-FPI-1547 Injection",
          "type": "DRUG"
        },
        {
          "name": "[225Ac]-FPI-1434 Injection multi-dose",
          "type": "DRUG"
        },
        {
          "name": "FPI-1175 Infusion",
          "type": "BIOLOGICAL"
        },
        {
          "name": "[225Ac]-FPI-1434 Injection single-dose",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "Fusion Pharmaceuticals Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 78,
      "start_date": "2019-01-17",
      "completion_date": "2025-12-03",
      "has_results": false,
      "last_update_posted_date": "2026-01-07",
      "last_synced_at": "2026-10-15T20:56:03.532Z",
      "location_count": 7,
      "location_summary": "Duarte, California • Boston, Massachusetts • Minneapolis, Minnesota + 4 more",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Minneapolis",
          "state": "Minnesota"
        },
        {
          "city": "Buffalo",
          "state": "New York"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03746431"
    },
    {
      "nct_id": "NCT03890731",
      "title": "A Clinical Study of Regorafenib in Participants Who Have Been Treated in Previous Bayer-sponsored Regorafenib Studies That Have Been Completed",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Solid Cancer"
      ],
      "interventions": [
        {
          "name": "BAY73-4506 (Regorafenib, Stivarga)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bayer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 6,
      "start_date": "2019-04-02",
      "completion_date": "2023-02-28",
      "has_results": true,
      "last_update_posted_date": "2024-04-02",
      "last_synced_at": "2026-10-15T20:56:03.532Z",
      "location_count": 1,
      "location_summary": "Tampa, Florida",
      "locations": [
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03890731"
    },
    {
      "nct_id": "NCT04511039",
      "title": "Trifluridine/Tipiracil and Talazoparib for the Treatment of Patients With Locally Advanced or Metastatic Colorectal or Gastroesophageal Cancer",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Advanced Malignant Solid Neoplasm",
        "Clinical Stage III Gastroesophageal Junction Adenocarcinoma",
        "Clinical Stage IV Gastroesophageal Junction Adenocarcinoma",
        "Clinical Stage IVA Gastroesophageal Junction Adenocarcinoma",
        "Clinical Stage IVB Gastroesophageal Junction Adenocarcinoma A",
        "Locally Advanced Colorectal Carcinoma",
        "Locally Advanced Gastroesophageal Junction Adenocarcinoma",
        "Metastatic Colorectal Adenocarcinoma",
        "Metastatic Gastroesophageal Junction Adenocarcinoma",
        "Pathologic Stage III Gastroesophageal Junction Adenocarcinoma",
        "Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma",
        "Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma",
        "Pathologic Stage IV Gastroesophageal Junction Adenocarcinoma",
        "Pathologic Stage IVA Gastroesophageal Junction Adenocarcinoma",
        "Pathologic Stage IVB Gastroesophageal Junction Adenocarcinoma",
        "Postneoadjuvant Therapy Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVA Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Postneoadjuvant Therapy Stage IVB Gastroesophageal Junction Adenocarcinoma AJCC v8",
        "Stage III Colorectal Cancer AJCC v8",
        "Stage IIIA Colorectal Cancer AJCC v8",
        "Stage IIIB Colorectal Cancer AJCC v8",
        "Stage IIIC Colorectal Cancer AJCC v8",
        "Stage IV Colorectal Cancer AJCC v8",
        "Stage IVA Colorectal Cancer AJCC v8",
        "Stage IVB Colorectal Cancer AJCC v8",
        "Stage IVC Colorectal Cancer AJCC v8"
      ],
      "interventions": [
        {
          "name": "Trifluridine and Tipiracil Hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "Talazoparib Tosylate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Roswell Park Cancer Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 45,
      "start_date": "2021-06-08",
      "completion_date": "2029-04-01",
      "has_results": false,
      "last_update_posted_date": "2026-05-04",
      "last_synced_at": "2026-10-15T20:56:03.532Z",
      "location_count": 1,
      "location_summary": "Buffalo, New York",
      "locations": [
        {
          "city": "Buffalo",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04511039"
    },
    {
      "nct_id": "NCT05848739",
      "title": "A Phase 1-2 of ST316 With Selected Advanced Unresectable and Metastatic Solid Tumors",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Colon Cancer",
        "Metastatic Colon Cancer"
      ],
      "interventions": [
        {
          "name": "ST316",
          "type": "DRUG"
        },
        {
          "name": "FOLFIRI regimen & bevacizumab",
          "type": "DRUG"
        },
        {
          "name": "Fruquintinib",
          "type": "DRUG"
        },
        {
          "name": "Lonsurf & bevacizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Sapience Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 130,
      "start_date": "2023-06-05",
      "completion_date": "2027-12-31",
      "has_results": false,
      "last_update_posted_date": "2026-07-22",
      "last_synced_at": "2026-10-15T20:56:03.532Z",
      "location_count": 11,
      "location_summary": "Birmingham, Alabama • Los Angeles, California • Denver, Colorado + 8 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05848739"
    }
  ]
}